Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | LOX | P28300 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | AKT2 | P31751 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16691262 | 0.86 | HRH3 (0.43) | HRH3KCNH2MKNK1MKNK2LOX | |
| SCHEMBL7464016 | 0.79 | PAICS (0.48) | FAAHMKNK1MKNK2TDO2 | |
| SCHEMBL1642262 | 0.77 | ACACB (0.57) | — | |
| SCHEMBL10231904 | 0.75 | NAAA (0.57) | FAAH | |
| SCHEMBL624868 | 0.75 | LOX (0.42) | HRH3KCNH2MKNK1MKNK2LOX | |
| SCHEMBL16924081 | 0.75 | LOX (0.43) | HRH3KCNH2LOXLOXL2NAMPT | |
| SCHEMBL15147591 | 0.75 | PDGFRB (0.44) | HRH3LOXLOXL2 | |
| SCHEMBL3651197 | 0.75 | LOX (0.46) | HRH3LOXLOXL2 | |
| SCHEMBL30748869 | 0.75 | LOX (0.46) | HRH3LOXLOXL2 | |
| SCHEMBL625001 | 0.75 | DGAT1 (0.46) | HRH3DGAT1KCNH2LOXLOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389536-B2 | Positive allosteric modulators (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE, INC. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | GRM5, GRM1, GRM2 | FAAH 3207/4885HRH3 502/4885DGAT1 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.